1. Multidose Stereotactic Radiosurgery (9 Gy × 3) of the Postoperative Resection Cavity for Treatment of Large Brain Metastases
- Author
-
Claudia Scaringi, Vincenzo Esposito, Gaetano Lanzetta, Riccardo Maurizi Enrici, Maurizio Salvati, Enrico Clarke, Alessandro Bozzao, Antonino Raco, and Giuseppe Minniti
- Subjects
adverse effects/methods ,aged ,brain ,brain neoplasms ,breast neoplasms ,carcinoma ,colonic neoplasms ,e aged ,female ,humans ,kidney neoplasms ,local ,lung neoplasms ,male ,melanoma ,methods ,mortality/pathology/secondary/surgery ,neoplasm recurrence ,non-small-cell lung ,pathology ,pathology/radiation effects ,postoperative care ,radiation injuries ,radiosurgery ,renal cell ,salvage therapy ,tumor burden ,Male ,Cancer Research ,Lung Neoplasms ,medicine.medical_treatment ,Carcinoma, Non-Small-Cell Lung ,Clinical endpoint ,Melanoma ,Cause of death ,Radiation ,Brain Neoplasms ,Brain ,Middle Aged ,Kidney Neoplasms ,Tumor Burden ,Oncology ,Colonic Neoplasms ,Female ,Radiology ,medicine.medical_specialty ,Breast Neoplasms ,Radiosurgery ,Breast cancer ,medicine ,Carcinoma ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiation Injuries ,Carcinoma, Renal Cell ,Aged ,Postoperative Care ,Salvage Therapy ,business.industry ,medicine.disease ,Surgery ,Radiation therapy ,Neoplasm Recurrence, Local ,business ,Brain metastasis - Abstract
Purpose To evaluate the clinical outcomes with linear accelerator-based multidose stereotactic radiosurgery (SRS) to large postoperative resection cavities in patients with large brain metastases. Methods and Materials Between March 2005 to May 2012, 101 patients with a single brain metastasis were treated with surgery and multidose SRS (9 Gy × 3) for large resection cavities (>3 cm). The target volume was the resection cavity with the inclusion of a 2-mm margin. The median cavity volume was 17.5 cm 3 (range, 12.6-35.7 cm 3 ). The primary endpoint was local control. Secondary endpoints were survival and distant failure rates, cause of death, performance measurements, and toxicity of treatment. Results With a median follow-up of 16 months (range, 6-44 months), the 1-year and 2-year actuarial survival rates were 69% and 34%, respectively. The 1-year and 2-year local control rates were 93% and 84%, with respective incidences of new distant brain metastases of 50% and 66%. Local control was similar for radiosensitive (non-small cell lung cancer and breast cancer) and radioresistant (melanoma and renal cell cancer) brain metastases. On multivariate Cox analysis stable extracranial disease, breast cancer histology, and Karnofsky performance status >70 were associated with significant survival benefit. Brain radionecrosis occurred in 9 patients (9%), being symptomatic in 5 patients (5%). Conclusions Adjuvant multidose SRS to resection cavity represents an effective treatment option that achieves excellent local control and defers the use of whole-brain radiation therapy in selected patients with large brain metastases.
- Published
- 2013